← All trials
NCT05587361
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Nov 1, 2025
- Completion date
- Nov 1, 2025
- First posted
- Oct 20, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OklahomaLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- Duke UniversityCollaborator
- Oklahoma State UniversityCollaborator
- University of OklahomaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.